Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

168
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
168
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

193
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
193
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

171
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
171
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

195
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
195
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redo-TAVR (TAV-in-TAV) Best Practices Part 1: Short-in-Short and Short-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026
Same author

Redo-TAVR (TAV-in-TAV) Best Practices Part 2: Tall-in-Short and Tall-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026
Same author

Preemptive cardioprotection with a small molecule in rodents that suppresses genes predictive of heart failure.

Science advances·2026
Same author

Ethnicity and its impact on presentation and outcomes in patients with spontaneous coronary artery dissection from the Australian-New Zealand registry.

Heart (British Cardiac Society)·2026
Same author

Machine Learning for Cardiovascular Risk Prediction: A Practical Primer for Clinicians.

Heart, lung & circulation·2026
Same author

Cardiovascular drug development: role of Mendelian randomization.

European heart journal·2026
Same journal

Dual antihypertensive fixed-dose combinations approved for first-line use on the Pharmaceutical Benefits Scheme.

Australian prescriber·2026
Same journal

Capivasertib for locally advanced or metastatic breast cancer.

Australian prescriber·2026
Same journal

Diagnosis and management of irritable bowel syndrome.

Australian prescriber·2026
Same journal

Stopping antidepressants: when and how.

Australian prescriber·2026
Same journal

Emergency contraception: an overview.

Australian prescriber·2026
Same journal

Sodium valproate: balancing benefits and risks especially in people of childbearing potential.

Australian prescriber·2026
See all related articles

Related Experiment Video

Updated: Jan 5, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

744

Amiodarone in the aged.

Meera Srinivasan1,2,3, Laura Ahmad1,2,3, Ravinay Bhindi1,2,3

  • 1Royal North Shore Hospital.

Australian Prescriber
|October 22, 2019
PubMed
Summary
This summary is machine-generated.

Amiodarone effectively treats arrhythmias but carries risks, especially for elderly patients. Careful patient selection, monitoring, and consideration of drug interactions are crucial to mitigate adverse effects.

Keywords:
amiodaroneantiarrhythmic drugsarrhythmiaatrial fibrillation

More Related Videos

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

3.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.3K

Related Experiment Videos

Last Updated: Jan 5, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

744
Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

3.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.3K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Amiodarone is a potent antiarrhythmic medication.
  • Its use is associated with significant adverse effects, particularly in elderly populations.

Purpose of the Study:

  • To highlight the risks and considerations for using amiodarone.
  • To provide guidance on appropriate patient selection and monitoring.

Main Methods:

  • Review of amiodarone's efficacy and adverse event profile.
  • Clinical guidelines and expert recommendations for amiodarone use.

Main Results:

  • Amiodarone is highly effective for arrhythmias but not recommended solely for rate control.
  • Contraindications include significant conduction disease, liver/pulmonary issues, and hyperthyroidism.
  • Potential drug interactions and prolonged toxicity post-discontinuation require attention.

Conclusions:

  • Amiodarone necessitates careful consideration, especially in older patients.
  • Consultation with a cardiologist is advised before initiating amiodarone.
  • Vigilant clinical and biochemical monitoring is essential for early detection of complications.